---
layout: post
title: "【图解年报】仁和药业：2021年归母净利润同比增长14.6%，约为6.7亿元"
date: 2022-04-25 19:12:24 +0800
categories: dongfangcaifuChoiceshuju
tags: 东方财富Choice数据新闻
---
<p>仁和药业于2022年4月26日披露年报，公司2021年实现营业总收入49.4亿，同比增长15.4%；实现归母净利润6.7亿，同比增长14.6%；每股收益为0.48元。</p><img id="image7" class="autoimg" src="https://dfscdn.dfcfw.com/download/D261A1447AEB421C0770F101514ACACBFC_w800h400.jpg" alt=""><p style="color:#61768C;font-size:0.9em;"></p><img id="image9" class="autoimg" src="https://dfscdn.dfcfw.com/download/D248C0781553D502EC7D424D27225867BA_w800h400.jpg" alt=""><p><strong>期间费用率下降2.3%</strong></p><p>公司2021年营业成本30.6亿，同比增长17.8%，高于营业收入15.4%的增速，导致毛利率下降1.2%。期间费用率为17.3%，较去年下降2.3%。</p><img id="image12" class="autoimg" src="https://dfscdn.dfcfw.com/download/D2710636C1FD705EBEED6D7428BACE9DF6_w800h400.jpg" alt=""><p><strong>本期“药品”营收贡献较大 </strong></p><p>从业务结构来看，“药品”是企业营业收入的主要来源。具体而言，“药品”营业收入为37.1亿，营收占比为76.6%，毛利率为37.4%。</p><img id="image15" class="autoimg" src="https://dfscdn.dfcfw.com/download/D24E527942C074C2CC7DB6F3768832AC84_w800h400.jpg" alt=""><img id="image17" class="autoimg" src="https://dfscdn.dfcfw.com/download/D2A19F6DADD1E922029F3F20003759A78B_w800h400.jpg" alt=""><p style="font-weight:bold;"></p><p style="margin: 10px 0; color: #999">免责声明：本文基于大数据生产，仅供参考，不构成任何投资建议，据此操作风险自担。</p><style>.autoimg {display: block;border: 0;max-width: 100%;margin: 0 auto;} .tbl {border-collapse: collapse;border-spacing: 0;text-align: center;width: 100% !important;} .tbl tr th, .tbl tr td {border: 1px solid #d8e6ff;padding: 5px;text-align: center;} .tbl tr th {color: #fff;background-color: #1c65b0;vertical-align: middle;} .tbl tr td {color: #000;background-color: #fff;} .imgtitle {text-indent: 0;text-align: center;color: #2395F1;} .autosrc {color: #999;display: block;text-align: center;margin-bottom: 5px;}</style>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204252357418278>

[返回东方财富Choice数据新闻](//finews.withounder.com/category/dongfangcaifuChoiceshuju.html)｜[返回首页](//finews.withounder.com/)